<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Ampligen,Ampligen.png,Pharmacology,List of portals,1960,1970,1980,1986,1987,1988,1991" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Ampligen - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Ampligen</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../a/m/p/Image%7EAmpligen_structure.png_1e7b.html" class="image" title=""><img src="../../../upload/thumb/3/31/Ampligen_structure.png/200px-Ampligen_structure.png" alt="" width="200" height="112" longdesc="../../../a/m/p/Image%7EAmpligen_structure.png_1e7b.html" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Ampligen</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">5'-Inosinic acid, homopolymer, complex with 5'-cytidylic acid polymer with 5'-uridylic acid (1:1)</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=38640-92-5&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=38640-92-5&amp;rn=1" rel="nofollow">38640-92-5</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=38077" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=38077" rel="nofollow">38077</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>28</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>40</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><sub>9</sub><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sub>25</sub><a href="../../../p/h/o/Phosphorus.html" title="Phosphorus"><span style="color: rgb(127,63,0); font-weight: bold;">P</span></a><sub>3</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">995.584</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../s/y/n/Synonym.html" title="Synonym">Synonyms</a></td>
<td bgcolor="#EEEEEE">Atvogen<br />
Poly(inosinic acid) poly(cytidylic(12), uridylic)acid</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>?</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE"></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">IV</td>
</tr>
</table>
<p><b>Ampligen</b>, also known as <b>Atvogen</b> and <b>polyI:polyC12U</b>, is an experimental <a href="../../../a/n/t/Antiviral_drug.html" title="Antiviral drug">antiviral</a> and <a href="../../../i/m/m/Immunomodulator.html" title="Immunomodulator">immunomodulatory</a> <a href="../../../r/n/a/RNA_78c4.html#Double-stranded_RNA" title="RNA">double stranded RNA</a> <a href="../../../d/r/u/Drug.html" title="Drug">drug</a> developed by HEMISPHERx Biopharma, Inc. It is believed to be of use mainly in the treatment of <a href="../../../c/h/r/Chronic_Fatigue_Syndrome_baf5.html" title="Chronic Fatigue Syndrome">Chronic Fatigue Syndrome</a> (CFS) and <a href="../../../h/i/v/HIV_abc5.html" title="HIV">HIV</a>, and is subject to some controversy.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Mechanism_of_action"><span class="tocnumber">2</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-1"><a href="#Clinical_trials_and_approval_status"><span class="tocnumber">3</span> <span class="toctext">Clinical trials and approval status</span></a></li>
<li class="toclevel-1"><a href="#Impact"><span class="tocnumber">4</span> <span class="toctext">Impact</span></a></li>
<li class="toclevel-1"><a href="#Side_effects_and_safety"><span class="tocnumber">5</span> <span class="toctext">Side effects and safety</span></a></li>
<li class="toclevel-1"><a href="#Controversy"><span class="tocnumber">6</span> <span class="toctext">Controversy</span></a></li>
<li class="toclevel-1"><a href="#Other_uses"><span class="tocnumber">7</span> <span class="toctext">Other uses</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">8</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">9</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">10</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>Ampligen was developed in the <a href="../../../1/9/6/1960.html" title="1960">1960s</a> after <a href="../../../m/e/r/Merck_%26_Co._6c38.html" title="Merck &amp; Co.">Merck &amp; Co.</a> had discovered a double-stranded <a href="../../../r/n/a/RNA_78c4.html" title="RNA">RNA</a> compound that inhibited tumor growth and induced interferon production. In the mid-<a href="../../../1/9/7/1970.html" title="1970">1970s</a>, <a href="../../../j/o/h/Johns_Hopkins_University_14b6.html" title="Johns Hopkins University">Johns Hopkins University</a> researchers redesigned the <a href="../../../d/s/r/DsRNA_0789.html" title="DsRNA">dsRNA</a> molecule to overcome the toxicities of the Merck compound. By adding a small uridylic acid molecule at a specific interval along the molecule chain, the compound was detoxified, and Ampligen (AMPLIfied GENetic activity) was born.<sup id="_ref-kitei_0" class="reference"><a href="#_note-kitei" title="">[1]</a></sup></p>
<p>In the late <a href="../../../1/9/8/1980.html" title="1980">1980s</a>, Dr. Carter and his company, Hemispherx Research, Inc., were pursuing human therapeutic uses for Ampligen, as well as non-therapeutic uses, such as diagnostic testing for <a href="../../../h/i/v/HIV_abc5.html" title="HIV">HIV</a> and plant protections from pathogens.<sup id="_ref-hemospherx_0" class="reference"><a href="#_note-hemospherx" title="">[2]</a></sup> In <a href="../../../1/9/8/1987.html" title="1987">1987</a>, Dr. Carter made a presentation to <a href="../../../p/h/i/Philip_Morris_USA_81ed.html" title="Philip Morris USA">Philip Morris USA</a> suggesting the possible use of Ampligen in treating tobacco to make a safe cigarette.<sup id="_ref-hemospherx_1" class="reference"><a href="#_note-hemospherx" title="">[2]</a></sup></p>
<p>Ampligen was first used in major clinical trials in America in early <a href="../../../1/9/8/1988.html" title="1988">1988</a>, after <a href="../../../d/u/p/DuPont_9a74.html" title="DuPont">DuPont</a> had invested <a href="../../../u/n/i/United_States_Dollar_68fe.html" title="United States Dollar">$</a>30 million in Hemispherx. Initial success was followed by difficulties in persuading the <a href="../../../f/d/a/FDA_274c.html" title="FDA">FDA</a> to permit large scale trials. By <a href="../../../1/9/9/1991.html" title="1991">1991</a>, it was thought that the chance of approval for a large trial being conducted in the USA had gone. Hemispherx then began to move clinical trials to <a href="../../../c/a/n/Canada.html" title="Canada">Canada</a> and <a href="../../../b/e/l/Belgium.html" title="Belgium">Belgium</a>.<sup id="_ref-johnson_0" class="reference"><a href="#_note-johnson" title="">[3]</a></sup> In Belgium, Ampligen has been available for use since the drug's trial beginning in <a href="../../../m/a/y/May_1996.html" title="May 1996">May 1996</a>. It has also been available under Canada's Emergency Drug Release Program for both <a href="../../../c/h/r/Chronic_Fatigue_Syndrome_baf5.html" title="Chronic Fatigue Syndrome">Chronic Fatigue Syndrome</a> (CFS) and HIV treatment since <a href="../../../1/9/9/1996.html" title="1996">1996</a>, with marketing rights controlled by Biovail Corporation International.<sup id="_ref-biovail_0" class="reference"><a href="#_note-biovail" title="">[4]</a></sup></p>
<p>An agreement between the Spanish company Esteve and Hemispherx in <a href="../../../2/0/0/2002.html" title="2002">2002</a> gave Esteve the rights to perform clinical trials at their own cost in <a href="../../../s/p/a/Spain.html" title="Spain">Spain</a>, <a href="../../../p/o/r/Portugal.html" title="Portugal">Portugal</a>, and <a href="../../../a/n/d/Andorra.html" title="Andorra">Andorra</a>.<sup id="_ref-esteve_0" class="reference"><a href="#_note-esteve" title="">[5]</a></sup></p>
<p>Bioclones (PTY) Ltd, a <a href="../../../u/k/_/UK_7642.html" title="UK">UK</a> based company, was granted the exclusive marketing rights to Ampligen in the <a href="../../../u/n/i/United_Kingdom_5ad7.html" title="United Kingdom">United Kingdom</a>, <a href="../../../r/e/p/Republic_of_Ireland_10e7.html" title="Republic of Ireland">Ireland</a>, and several countries in the Southern Hemisphere.<sup id="_ref-bioclones_0" class="reference"><a href="#_note-bioclones" title="">[6]</a></sup></p>
<p>Ampligen is currently undergoing <a href="../../../c/l/i/Clinical_trials.html" title="Clinical trials">clinical trials</a> in the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a>.<sup id="_ref-2005SEC_0" class="reference"><a href="#_note-2005SEC" title="">[7]</a></sup></p>
<p><a name="Mechanism_of_action" id="Mechanism_of_action"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Mechanism of action">edit</a>]</span> <span class="mw-headline">Mechanism of action</span></h2>
<div class="messagebox cleanup metadata">
<p><b>This article or section is in need of attention from an expert on the subject.</b><br />
<a href="../../../w/i/k/Wikipedia%7EWikiProject_Pharmacology_9728.html" title="Wikipedia:WikiProject Pharmacology">WikiProject Pharmacology</a> or the <a href="../../../p/h/a/Portal%7EPharmacology_df95.html" title="Portal:Pharmacology">Pharmacology Portal</a> may be able to help recruit one.<br />
If a more appropriate <a href="../../../w/i/k/Wikipedia%7EWikiProject_751e.html" title="Wikipedia:WikiProject">WikiProject</a> or <a href="../../../l/i/s/Portal%7EList_of_portals_00a1.html" title="Portal:List of portals">portal</a> exists, please adjust this template accordingly.</p>
</div>
<p>In a 1986 Business Description of Hem Research the mechanism of action of <a href="../../../d/s/r/DsRNA_0789.html" title="DsRNA">dsRNA</a> is described as follows: "When introduced into the body, a <a href="../../../d/s/r/DsRNA_0789.html" title="DsRNA">dsRNA</a>, as a large <a href="../../../n/u/c/Nucleic_acid.html" title="Nucleic acid">nucleic acid</a>, will initiate a two step proces equivalent to an immune system response. The compound appears as a <a href="../../../v/i/r/Virus.html" title="Virus">virus</a> to the human <a href="../../../i/m/m/Immune_system.html" title="Immune system">immune system</a> and thus induces a normal immune reaction, including the induction of various <a href="../../../w/h/i/White_blood_cell.html" title="White blood cell">white blood cell</a> activities and the production of the appropriate <a href="../../../l/y/m/Lymphokines.html" title="Lymphokines">lymphokines</a>. The reaction approximates a natural <a href="../../../i/m/m/Immune_response.html" title="Immune response">immune response</a> in that the immune factors appear at their normal levels of concentration within the body.</p>
<p>The second step of this process results from the <a href="../../../d/s/r/DsRNA_0789.html" title="DsRNA">dsRNA</a> chemical structure. Certain biological pathways which are set in motion during immune system reactions require the presence of a <a href="../../../c/a/t/Catalyst.html" title="Catalyst">catalyst</a> to complete the pathway. dsRNA's serve that catalyst function." <sup id="_ref-0" class="reference"><a href="#_note-0" title="">[8]</a></sup></p>
<p>The mechanism of action in relation to CFS is not entirely clear, but it is known to act on two important enzyme systems, one of which is the 2-5 Synthetase/<a href="../../../r/n/a/RNase_L_d0da.html" title="RNase L">RNase L</a> anti-viral pathway. Research increasingly shows that the upregulation of this pathway is an important factor in the development of CFS.<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[9]</a></sup> The downregulation of this pathway leads to the <a href="../../../i/m/m/Immune_system.html" title="Immune system">immune system</a> being better able to destroy viral <a href="../../../r/n/a/RNA_78c4.html" title="RNA">RNA</a> and accelerates the <a href="../../../a/p/o/Apoptosis.html" title="Apoptosis">apoptosis</a> of virally compromised cells<sup class="noprint Template-Fact"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup>. Ampligen must be received <a href="../../../i/n/t/Intravenously.html" title="Intravenously">intravenously</a>, but Hemispherx is researching an oral form of the drug.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[10]</a></sup> It is generally administered twice weekly for periods of one year or greater.</p>
<p><a name="Clinical_trials_and_approval_status" id="Clinical_trials_and_approval_status"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Clinical trials and approval status">edit</a>]</span> <span class="mw-headline">Clinical trials and approval status</span></h2>
<p>The randomized segment of the AMP 516 <a href="../../../c/l/i/Clinical_trial.html#Phase_III" title="Clinical trial">Phase III</a> <a href="../../../c/l/i/Clinical_trial.html" title="Clinical trial">clinical trial</a> in the USA was completed in 2004.<a href="http://sec.edgar-online.com/2004/03/22/0000891092-04-001352/Section8.asp" class="external autonumber" title="http://sec.edgar-online.com/2004/03/22/0000891092-04-001352/Section8.asp" rel="nofollow">[1]</a> At the moment, an Open Label Study of Ampligen in CFS is recruiting <a href="http://www.clinicaltrials.gov/ct/show/NCT00215813" class="external autonumber" title="http://www.clinicaltrials.gov/ct/show/NCT00215813" rel="nofollow">[2]</a>. These studies are typically used when the controlled trial has ended and treatment is continued so that the subjects and the controls may continue to receive the benefits of the investigational drug until marketing approval is obtained.<a href="http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html" class="external autonumber" title="http://www.fda.gov/oc/ohrt/irbs/drugsbiologics.html" rel="nofollow">[3]</a> American <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) approval of Ampligen for the treatment of CFS is not yet available, and no <a href="../../../n/e/w/New_Drug_Application_f9fe.html" title="New Drug Application">New Drug Application</a> (NDA) has yet been filed. Hemispherx management has most recently targeted mid-2007 for the completion of the filing a new drug application, having missed several target deadlines for an NDA filing in the past, including the end of 2005, the third quarter of 2006 and the first quarter of the year 2007.<a href="http://sec.edgar-online.com/2006/01/03/0000946644-06-000001/Section4.asp" class="external autonumber" title="http://sec.edgar-online.com/2006/01/03/0000946644-06-000001/Section4.asp" rel="nofollow">[4]</a></p>
<p><a name="Impact" id="Impact"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Impact">edit</a>]</span> <span class="mw-headline">Impact</span></h2>
<p>Approximately 760 patients have received Ampligen as part of clinical trials in the US, representing about 75,000 doses. Some patients have reported a complete recovery, with others reporting clear and measurable improvements <a href="http://www.cfids-me.org/aacfs/ampligen.html" class="external autonumber" title="http://www.cfids-me.org/aacfs/ampligen.html" rel="nofollow">[5]</a>, although success has not been universal. More common benefits include improved <a href="../../../c/o/g/Cognitive.html" title="Cognitive">cognitive</a> skills, an increase in energy, and greater oxygen uptake. These improvements can be measured on the <a href="../../../k/a/r/Karnofsky_score.html#Karnofsky_scoring" title="Karnofsky score">Karnofsky</a> scale <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7893988" class="external autonumber" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7893988" rel="nofollow">[6]</a><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8148460" class="external autonumber" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8148460" rel="nofollow">[7]</a>. Some studies suggest that Ampligen is most effective against a certain subset of CFS patients, those with severe debilitation<sup class="noprint Template-Fact"><a href="../../../c/i/t/Wikipedia%7ECiting_sources_8ba4.html" title="Wikipedia:Citing sources"><span title="This claim needs references to reliable sources since February 2007" style="white-space: nowrap;">[<i>citation needed</i>]</span></a></sup>. According to Dr Paul Cheney, a CFS researcher, the chances of a response appear to be "2 chances in 3 and that might be raised a little bit if one targets a subset of patients, specifically ones that are within the first 5 years of their illness who have abrupt onset and who may have activation of this RNase L pathway" <a href="http://www.co-cure.org/cheney.htm" class="external autonumber" title="http://www.co-cure.org/cheney.htm" rel="nofollow">[8]</a>.</p>
<p><a name="Side_effects_and_safety" id="Side_effects_and_safety"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Side effects and safety">edit</a>]</span> <span class="mw-headline">Side effects and safety</span></h2>
<p>Hemispherx consider that Ampligen has been "generally well tolerated", with a "low incidence of clinical toxicity", particularly when compared to the toxicity of the diseases it is used to treat. "No serious safety issues have resulted from the administration of ~75,000 doses IV (most commonly 400 mg) twice weekly for up to one year periods or greater. Animal toxicity studies support this observation in humans with primates demonstrating the greatest margin of safety."<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[11]</a></sup> A mild <a href="../../../f/l/u/Flushing_%28physiology%29.html" title="Flushing (physiology)">flushing</a> reaction has occurred in about 15% of patients, and other reported <a href="../../../a/d/v/Adverse_effect_%28medicine%29.html" title="Adverse effect (medicine)">side effects</a> include <a href="../../../f/l/u/Flushing.html" title="Flushing">flushing</a>, <a href="../../../c/h/i/Chills.html" title="Chills">chills</a>, <a href="../../../f/e/v/Fever.html" title="Fever">fever</a>, <a href="../../../m/a/l/Malaise.html" title="Malaise">malaise</a>, <a href="../../../l/e/u/Leukopenia.html" title="Leukopenia">leukopenia</a>, <a href="../../../n/e/u/Neutropenia.html" title="Neutropenia">neutropenia</a> and <a href="../../../l/e/u/Leukocytosis.html" title="Leukocytosis">leukocytosis</a>. A full list is available on the Hemispherx website.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[12]</a></sup> The extent of these side effects is unknown. According to Hemispherx, side effects usually subside within "several months".</p>
<p><a name="Controversy" id="Controversy"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Controversy">edit</a>]</span> <span class="mw-headline">Controversy</span></h2>
<p>Ampligen has been surrounded by controversy since it was first discovered, in particular as to why it never completed FDA trials despite showing definite improvements in a number of patients.</p>
<p>Ampligen's first and most famous detractor was "Asensio" <a href="http://www.asensioexposed.com/illwill.htm" class="external autonumber" title="http://www.asensioexposed.com/illwill.htm" rel="nofollow">[9]</a><a href="http://www.aegis.com/NEWS/PR/1999/PR990514.html" class="external autonumber" title="http://www.aegis.com/NEWS/PR/1999/PR990514.html" rel="nofollow">[10]</a>. On September 30, 1998, Hemispherx Biopharma filed a multi-count complaint against Manuel P. Asensio, Asensio &amp; Company, Inc. The action included claims of <a href="../../../d/e/f/Defamation.html" title="Defamation">defamation</a>, disparagement, tortuous interference with existing and prospective business relations and <a href="../../../c/o/n/Conspiracy_%28civil%29.html" title="Conspiracy (civil)">conspiracy</a>, arising out of Asensio's false and defamatory statements. The complaint further alleged that Asensio defamed and disparaged Hemispherx in furtherance of a manipulative, deceptive and unlawful <a href="../../../s/h/o/Short_selling.html" title="Short selling">short selling</a> scheme in August and September, 1998. A jury verdict disallowed the claims against Hemispherx for defamation and disparagement and the court granted a <a href="../../../d/i/r/Directed_verdict.html" title="Directed verdict">directed verdict</a> on the <a href="../../../c/o/u/Counterclaim.html" title="Counterclaim">counterclaim</a>. Hemispherx now anticipate the scheduling of a new trial against Asensio for defamation and disparagement in the Philadelphia Common Pleas Court (10Q September 30, 2006, p.33)<a href="http://www.sec.gov/Archives/edgar/data/946644/000114420406045520/v056547_10-q.txt" class="external autonumber" title="http://www.sec.gov/Archives/edgar/data/946644/000114420406045520/v056547_10-q.txt" rel="nofollow">[11]</a>. Asensio still maintains a website documenting its allegations regarding the company.<a href="http://www.asensio.com/SiteAgreement.aspx?UrlReferrer=%2fSearchResults.aspx%3fSearch%3dampligen" class="external autonumber" title="http://www.asensio.com/SiteAgreement.aspx?UrlReferrer=%2fSearchResults.aspx%3fSearch%3dampligen" rel="nofollow">[12]</a></p>
<p>The conflict with Asensio also dragged in surprising bystanders, including <a href="../../../o/p/r/Oprah_Winfrey_92a2.html" title="Oprah Winfrey">Oprah Winfrey</a>, <a href="../../../s/e/c/Securities_and_Exchange_Commission_f519.html" title="Securities and Exchange Commission">Securities and Exchange Commission</a> Chairman <a href="../../../a/r/t/Arthur_Levitt_8134.html" title="Arthur Levitt">Arthur Levitt</a> and AIDS activist David Scondras. <a href="http://www.cfs-news.org/ampwsj00.htm#text" class="external autonumber" title="http://www.cfs-news.org/ampwsj00.htm#text" rel="nofollow">[13]</a></p>
<p>A stinging testimony before the Chronic Fatigue Syndrome Coordinating Committee (CFSCC) of the <a href="../../../u/2E/s/U.S._Department_of_Health_and_Human_Services_4ac0.html" title="U.S. Department of Health and Human Services">U.S. Department of Health and Human Services</a> on November 2, 1999 raised the question why Ampligen had never been <a href="../../../f/a/s/Fast-tracked.html" title="Fast-tracked">fast-tracked</a> by the US public health authorities.<a href="http://www.cfids-me.org/cfscc/amptestimony.html" class="external autonumber" title="http://www.cfids-me.org/cfscc/amptestimony.html" rel="nofollow">[14]</a></p>
<p>Many patients have been skeptical of results or have reported difficulties with Hemispherx.<a href="http://www.fda.gov/bbs/topics/ANSWERS/ANS00350.html" class="external autonumber" title="http://www.fda.gov/bbs/topics/ANSWERS/ANS00350.html" rel="nofollow">[15]</a><a href="http://www.geocities.com/cfsdays/beforamp.htm" class="external autonumber" title="http://www.geocities.com/cfsdays/beforamp.htm" rel="nofollow">[16]</a>. The company has also been accused of promising patients Ampligen free of charge when studies ended, but then refusing to supply it and pointing out that there is no mention of this claim in legal documents. <a href="http://www.cfs-news.org/amposler.htm" class="external autonumber" title="http://www.cfs-news.org/amposler.htm" rel="nofollow">[17]</a></p>
<p>According to Hemispherx, some trials have been poorly controlled and, accordingly, additional tests will be necessary for support of regulatory approvals. <a href="http://www.hemispherx.net/content/rnd/drug_candidates.htm" class="external autonumber" title="http://www.hemispherx.net/content/rnd/drug_candidates.htm" rel="nofollow">[18]</a></p>
<p>There have also been accusations that Hemispherx issue misleading results <a href="http://www.aegis.com/NEWS/PR/1999/PR990509.html" class="external autonumber" title="http://www.aegis.com/NEWS/PR/1999/PR990509.html" rel="nofollow">[19]</a> in attempts to create a wider market for their drugs, although this has never been proven.</p>
<p>It has on two occasions received warning letters from the <a href="../../../f/d/a/FDA_274c.html" title="FDA">FDA</a> regarding its promotion of Ampligen as safe and effective before approval from the <a href="../../../f/d/a/FDA_274c.html" title="FDA">FDA</a>.<a href="http://www.fda.gov/cder/warn/oct98/7146.pdf" class="external autonumber" title="http://www.fda.gov/cder/warn/oct98/7146.pdf" rel="nofollow">[20]</a><a href="http://www.fda.gov/cder/warn/july2000/dd8800.pdf" class="external autonumber" title="http://www.fda.gov/cder/warn/july2000/dd8800.pdf" rel="nofollow">[21]</a></p>
<p>In spite of all the controversy, Hemispherx Biopharma has never, by a judgement which has the force of <a href="../../../r/e/s/Res_judicata.html" title="Res judicata">res judicata</a>, been found guilty of illegal behaviour.</p>
<p><a name="Other_uses" id="Other_uses"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: Other uses">edit</a>]</span> <span class="mw-headline">Other uses</span></h2>
<p>Some alternative potential uses of Ampligen include fighting <a href="../../../a/v/i/Avian_Flu_cf47.html" title="Avian Flu">Avian Flu</a><sup id="_ref-Alibek_0" class="reference"><a href="#_note-Alibek" title="">[13]</a></sup>, <a href="http://www.cdc.gov/ncidod/EID/vol12no05/05-1480.htm" class="external autonumber" title="http://www.cdc.gov/ncidod/EID/vol12no05/05-1480.htm" rel="nofollow">[22]</a> <a href="http://www.hemispherx.net/Ampligen%20adjuvant%20Hideki.pdf" class="external autonumber" title="http://www.hemispherx.net/Ampligen%20adjuvant%20Hideki.pdf" rel="nofollow">[23]</a>, <a href="../../../a/i/d/AIDS_b1c7.html" title="AIDS">AIDS</a> <a href="http://www.clinicaltrials.gov/ct/show/NCT00035893?order=1" class="external autonumber" title="http://www.clinicaltrials.gov/ct/show/NCT00035893?order=1" rel="nofollow">[24]</a>, <a href="http://www.clinicaltrials.gov/ct/show/NCT00035581?order=5" class="external autonumber" title="http://www.clinicaltrials.gov/ct/show/NCT00035581?order=5" rel="nofollow">[25]</a>,<a href="http://www.aidsmap.com/en/docs/26E043C1-10CA-4FF7-BA24-77529D386442.asp" class="external autonumber" title="http://www.aidsmap.com/en/docs/26E043C1-10CA-4FF7-BA24-77529D386442.asp" rel="nofollow">[26]</a>, <a href="../../../h/e/p/Hepatitis_B_56eb.html" title="Hepatitis B">Hepatitis B</a> and <a href="../../../c/a/n/Cancer.html" title="Cancer">Cancer</a>, although studies have been limited. <a href="http://www.hemispherx.net/content/rnd/product_candidates.htm" class="external autonumber" title="http://www.hemispherx.net/content/rnd/product_candidates.htm" rel="nofollow">[27]</a> Other suggested uses include <a href="../../../e/b/o/Ebola.html" title="Ebola">Ebola</a> and <a href="../../../s/m/a/Small_Pox_711f.html" title="Small Pox">Small Pox</a>. <a href="http://www.wired.com/news/business/1,48444-1.html" class="external autonumber" title="http://www.wired.com/news/business/1,48444-1.html" rel="nofollow">[28]</a> Research by Bioclones (PTY) Ltd in collaboration with the <a href="../../../u/n/i/University_of_Wales_College_of_Medicine_263e.html" title="University of Wales College of Medicine">University of Wales College of Medicine</a> has suggested that Ampligen is also a powerful inducer of <a href="../../../d/e/n/Dendritic_cell.html" title="Dendritic cell">dendritic cell</a> maturation. <a href="http://www.bioclones.co.za/ampligen.htm" class="external autonumber" title="http://www.bioclones.co.za/ampligen.htm" rel="nofollow">[29]</a></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../c/h/r/Chronic_Fatigue_Syndrome_baf5.html" title="Chronic Fatigue Syndrome">Chronic Fatigue Syndrome</a></li>
<li><a href="../../../o/r/a/Oragen.html" title="Oragen">Oragen</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-kitei"><b><a href="#_ref-kitei_0" title="">^</a></b> Kitei, Mindy. <a href="http://www.cfs-news.org/kitei.htm" class="external text" title="http://www.cfs-news.org/kitei.htm" rel="nofollow">A History of Ampligen: The AIDS Drug No One Can Have</a>." <i>Philadelphia Magazine.</i> <a href="../../../o/c/t/October_1994.html" title="October 1994">October 1994</a>. Retrieved on <a href="../../../f/e/b/February_25.html" title="February 25">February 25</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-hemospherx">^ <a href="#_ref-hemospherx_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-hemospherx_1" title=""><sup><i><b>b</b></i></sup></a> "<a href="http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A&amp;" class="external text" title="http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A&amp;" rel="nofollow">Business Description: HEM Research, Inc.</a>" <a href="../../../1/9/8/1986.html" title="1986">1986</a>. Retrieved on <a href="../../../f/e/b/February_25.html" title="February 25">February 25</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-johnson"><b><a href="#_ref-johnson_0" title="">^</a></b> Johnson, Hillary. "<a href="http://www.cfs-news.org/amposler.htm" class="external text" title="http://www.cfs-news.org/amposler.htm" rel="nofollow">Osler's Web: Inside the Labyrinth of the Chronic Fatigue Syndrome Epidemic</a>." <a href="../../../1/9/9/1996.html" title="1996">1996</a>. <i><a href="../../../c/r/o/Crown_Publishing_Group_228f.html" title="Crown Publishing Group">Crown Publishing Group</a>.</i> Retrieved on <a href="../../../f/e/b/February_25.html" title="February 25">February 25</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-biovail"><b><a href="#_ref-biovail_0" title="">^</a></b> Melnyk, Eugene; Howling, Kenneth G. "<a href="http://www.biovail.com/english/Investor%20Relations/Latest%20News/default.asp?s=1&amp;state=showrelease&amp;releaseid=74228" class="external text" title="http://www.biovail.com/english/Investor%20Relations/Latest%20News/default.asp?s=1&amp;state=showrelease&amp;releaseid=74228" rel="nofollow">Biovail Acquires Ampligen Marketing Rights for Canada; New Treatment for Chronic Fatigue Syndrome</a>." <i>Biovail.</i> <a href="../../../f/e/b/February_11.html" title="February 11">February 11</a>, <a href="../../../2/0/0/2000.html" title="2000">2000</a>. Retrieved on <a href="../../../f/e/b/February_25.html" title="February 25">February 25</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-esteve"><b><a href="#_ref-esteve_0" title="">^</a></b> "<a href="http://www.secinfo.com/dSSer.2e.htm" class="external text" title="http://www.secinfo.com/dSSer.2e.htm" rel="nofollow">SEC Filing (Form S-3): Hemispherx Biopharma, Inc.</a>." <a href="../../../j/a/n/January_14.html" title="January 14">January 14</a>, <a href="../../../2/0/0/2003.html" title="2003">2003</a>. Retrieved on <a href="../../../f/e/b/February_25.html" title="February 25">February 25</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-bioclones"><b><a href="#_ref-bioclones_0" title="">^</a></b> "<a href="http://www.ingentaconnect.com/content/adis/rdd/2002/00000003/00000002/art00016" class="external text" title="http://www.ingentaconnect.com/content/adis/rdd/2002/00000003/00000002/art00016" rel="nofollow">Mismatched Double-Stranded RNA: Ampligen, Oragen, Polyi:Polyc12u</a>." <i>Drugs in R&amp;D.</i> <a href="../../../f/e/b/February_1.html" title="February 1">February 1</a>, <a href="../../../2/0/0/2002.html" title="2002">2002</a>. Retrieved on [{February 26]], <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-2005SEC"><b><a href="#_ref-2005SEC_0" title="">^</a></b> "<a href="http://www.sec.gov/Archives/edgar/data/946644/000114420406023585/v044836_10k-a.txt" class="external text" title="http://www.sec.gov/Archives/edgar/data/946644/000114420406023585/v044836_10k-a.txt" rel="nofollow">2005 SEC Filing (Form 10-K/A)</a>." For the fiscal year ended <a href="../../../d/e/c/December_31.html" title="December 31">December 31</a>, <a href="../../../2/0/0/2005.html" title="2005">2005</a>. Retrieved on <a href="../../../f/e/b/February_26.html" title="February 26">February 26</a>, <a href="../../../2/0/0/2007.html" title="2007">2007</a>.</li>
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <a href="http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A&amp;#p2" class="external text" title="http://tobaccodocuments.org/pm/2024986987-7026.html?pattern=ampligen%5Ba-z%5D%2A&amp;#p2" rel="nofollow">Business Description for Hem Research, Inc.</a> - tobaccodocuments.org</li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite style="font-style:normal" id="CITEREFWright.2C_MBChB.2C_DRCOG.2C_MRCGP.2C_DCH.2C_DIHom2002">Wright, MBChB, DRCOG, MRCGP, DCH, DIHom, Andrew J. (2002), <i><a href="http://www.immunesupport.com/library/print.cfm?ID=4016" class="external text" title="http://www.immunesupport.com/library/print.cfm?ID=4016" rel="nofollow">Chronic Fatigue Syndrome, Fibromyalgia and Associated Syndromes: Evidence for Their Organic Basis</a></i>, CFS Research</cite></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> <a href="http://www.chronicillnet.org/online/Ampligen.html" class="external text" title="http://www.chronicillnet.org/online/Ampligen.html" rel="nofollow">Stone-Cold Decade: Ampligen Finally Breaks Free of Red Tape -- in Canada</a> - Neenyah Ostrom</li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> <cite style="font-style:normal">Mitchell, W. (December 2006). "<a href="http://www.immunesupport.com/library/showarticle.cfm/id/7638/searchtext/ampligen" class="external text" title="http://www.immunesupport.com/library/showarticle.cfm/id/7638/searchtext/ampligen" rel="nofollow">Review of Ampligen® clinical trials in Chronic Fatigue Syndrome</a>". <i>Journal of Clinical Virology</i> <b>37, supp. 1</b>: S113. Retrieved on <a href="../../../2/0/0/2007.html" title="2007">2007</a>-<a href="../../../f/e/b/February_26.html" title="February 26">02-26</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Review+of+Ampligen%C2%AE+clinical+trials+in+Chronic+Fatigue+Syndrome&amp;rft.title=Journal+of+Clinical+Virology&amp;rft.jtitle=Journal+of+Clinical+Virology&amp;rft.date=December+2006&amp;rft.volume=37%2C+supp.+1&amp;rft.aulast=Mitchell&amp;rft.aufirst=W.&amp;rft.pages=S113&amp;rft_id=http%3A%2F%2Fwww.immunesupport.com%2Flibrary%2Fshowarticle.cfm%2Fid%2F7638%2Fsearchtext%2Fampligen">&#160;</span></li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> <a href="http://www.hemispherx.net/content/rnd/drug_candidates.htm" class="external text" title="http://www.hemispherx.net/content/rnd/drug_candidates.htm" rel="nofollow">Ampligen</a> - official Hemispherx site</li>
<li id="_note-Alibek"><b><a href="#_ref-Alibek_0" title="">^</a></b> Alibek K, Liu G. (2006 May). "<i><a href="http://www.cdc.gov/ncidod/EID/vol12no05/05-1480.htm" class="external text" title="http://www.cdc.gov/ncidod/EID/vol12no05/05-1480.htm" rel="nofollow">Biodefense shield and avian influenza</a></i>". Letter. Emerg Infect Dis.  Retrieved on <a href="../../../2/0/0/2007.html" title="2007">2007</a>-<a href="../../../d/e/c/December_14.html" title="December 14">12-14</a>.</li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/p/Ampligen.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://wwcoco.com/cfids/ampligen.html" class="external text" title="http://wwcoco.com/cfids/ampligen.html" rel="nofollow">Ampligen FAQ (1996)</a></li>
<li><a href="http://www.chronicillnet.org/online/Ampligen.html" class="external text" title="http://www.chronicillnet.org/online/Ampligen.html" rel="nofollow">Ampligen Debate</a></li>
<li><a href="http://www.hemispherx.net/content/rnd/drug_candidates.htm" class="external text" title="http://www.hemispherx.net/content/rnd/drug_candidates.htm" rel="nofollow">Hemispherx Ampligen Page</a></li>
<li><a href="http://www.cfs-news.org/kitei.htm" class="external text" title="http://www.cfs-news.org/kitei.htm" rel="nofollow">A History of Ampligen and its Creator</a></li>
<li><a href="http://www.esteve.es/EsteveFront/EST.do" class="external text" title="http://www.esteve.es/EsteveFront/EST.do" rel="nofollow">Esteve Home Page</a></li>
<li><a href="http://www.bioclones.co.za/ampligen.htm" class="external text" title="http://www.bioclones.co.za/ampligen.htm" rel="nofollow">Bioclones Ampligen Page</a></li>
<li><a href="http://www.immunesupport.com/library/showarticle.cfm/id/7638/searchtext/ampligen" class="external text" title="http://www.immunesupport.com/library/showarticle.cfm/id/7638/searchtext/ampligen" rel="nofollow">Review of ampligen® clinical trials in CFS</a></li>
<li><a href="http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=0000946644&amp;owner=include" class="external text" title="http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=0000946644&amp;owner=include" rel="nofollow">Hemispherx Biopharma SEC filings</a></li>
<li><a href="http://www.hemispherx.net/content/rnd/pdf/AMP_502.pdf" class="external text" title="http://www.hemispherx.net/content/rnd/pdf/AMP_502.pdf" rel="nofollow">Peer-reviewed Ampligen for CFS phase II trial article in Clinical Infectious Diseases 1994; 18 (Suppl. 1):S 88-95</a></li>
<li><a href="http://www.stocklemon.com/articles/10_23_02.html" class="external text" title="http://www.stocklemon.com/articles/10_23_02.html" rel="nofollow">Stock Lemon (2002)</a></li>
<li><a href="http://www.fool.com/news/foth/2002/foth021011.htm" class="external text" title="http://www.fool.com/news/foth/2002/foth021011.htm" rel="nofollow">Motley Fool (2002)</a></li>
</ul>

<!-- 
Pre-expand include size: 49217 bytes
Post-expand include size: 13765 bytes
Template argument size: 5557 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/m/p/Ampligen.html">http://en.wikipedia.org../../../a/m/p/Ampligen.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../p/h/a/Category%7EPharmacology_articles_needing_expert_attention_22a0.html" title="Category:Pharmacology articles needing expert attention">Pharmacology articles needing expert attention</a></span> | <span dir='ltr'><a href="../../../a/r/t/Category%7EArticles_with_unsourced_statements_since_February_2007_f7dc.html" title="Category:Articles with unsourced statements since February 2007">Articles with unsourced statements since February 2007</a></span> | <span dir='ltr'><a href="../../../a/l/l/Category%7EAll_articles_with_unsourced_statements_2f67.html" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="../../../d/r/u/Category%7EDrugs_b475.html" title="Category:Drugs">Drugs</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/m/p/Ampligen.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/m/p/Talk%7EAmpligen_d856.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Ampligen">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 19:49, 29 March 2007 by Wikipedia user <a href="../../../t/h/e/User%7EThedreamdied_b4b9.html" title="User:Thedreamdied">Thedreamdied</a>. Based on work by Wikipedia user(s) Georgedunn, <a href="../../../w/k/n/User%7EWknight94_8d60.html" title="User:Wknight94">Wknight94</a>, <a href="../../../d/e/r/User%7EDerek.cashman_b6d7.html" title="User:Derek.cashman">Derek.cashman</a>, <a href="../../../a/l/i/User%7EAlison_304c.html" title="User:Alison">Alison</a>, <a href="../../../t/h/e/User%7ETheroachman_a473.html" title="User:Theroachman">Theroachman</a>, <a href="../../../t/i/k/User%7ETikiwont_2b2d.html" title="User:Tikiwont">Tikiwont</a>, <a href="../../../w/a/m/User%7EWamper_4c05.html" title="User:Wamper">Wamper</a>, <a href="../../../a/v/b/User%7EAvb_3038.html" title="User:Avb">Avb</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, <a href="../../../p/g/k/User%7EPgk_d0c7.html" title="User:Pgk">Pgk</a>, <a href="../../../m/a/r/User%7EMarin655biclonesredlabs_dbab.html" title="User:Marin655biclonesredlabs">Marin655biclonesredlabs</a>, <a href="../../../p/o/r/User%7EPorkrind_126f.html" title="User:Porkrind">Porkrind</a>, <a href="../../../b/e/a/User%7EBean915_4c1c.html" title="User:Bean915">Bean915</a>, <a href="../../../s/c/i/User%7EScientist_15_8908.html" title="User:Scientist 15">Scientist 15</a>, <a href="../../../l/u/n/User%7ELuna_Santin_1cab.html" title="User:Luna Santin">Luna Santin</a>, Zarzine, <a href="../../../z/a/n/User%7EZanzibarlo_7c34.html" title="User:Zanzibarlo">Zanzibarlo</a>, <a href="../../../q/x/z/User%7EQxz_3066.html" title="User:Qxz">Qxz</a>, <a href="../../../e/a/g/User%7EEagle_101_bfb5.html" title="User:Eagle 101">Eagle 101</a>, <a href="../../../t/h/e/User%7EThe_Epopt_6905.html" title="User:The Epopt">The Epopt</a>, <a href="../../../c/m/d/User%7ECmdrObot_0605.html" title="User:CmdrObot">CmdrObot</a>, Fitzhugh, <a href="../../../b/b/e/User%7EBBerryhill_5732.html" title="User:BBerryhill">BBerryhill</a>, <a href="../../../m/o/n/User%7EMontco_3514.html" title="User:Montco">Montco</a>, <a href="../../../i/o/a/User%7EIoannes_Pragensis_cdfc.html" title="User:Ioannes Pragensis">Ioannes Pragensis</a>, Byetime and <a href="../../../e/l/o/User%7EElonka_d4b2.html" title="User:Elonka">Elonka</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
